Artificial Intelligence and Anticancer Drug Development-Keep a Cool Head

doi:10.3390/pharmaceutics16020211

. 2024 Jan 31;16(2):211.

doi: 10.3390/pharmaceutics16020211.

Artificial Intelligence and Anticancer Drug Development-Keep a Cool Head

Caroline Bailleux¹, Jocelyn Gal², Emmanuel Chamorey², Baharia Mograbi³, Gérard Milano⁴

Affiliations

¹ Centre Antoine Lacassagne, Oncology Departement Unit, University Côte d'Azur, 06000 Nice, France.
² Centre Antoine Lacassagne, Epidemiology and Biostatistics Department, University Côte d'Azur, 06000 Nice, France.
³ IRCAN Group, University Côte d'Azur, 06000 Nice, France.
⁴ Centre Antoine Lacassagne, University Côte d'Azur, 33 Avenue de Valombrose, 06189 Nice, France.

PMID: 38399265
PMCID: PMC10893490
DOI: 10.3390/pharmaceutics16020211

Artificial Intelligence and Anticancer Drug Development-Keep a Cool Head

Caroline Bailleux et al. Pharmaceutics. 2024.

. 2024 Jan 31;16(2):211.

doi: 10.3390/pharmaceutics16020211.

Authors

Caroline Bailleux¹, Jocelyn Gal², Emmanuel Chamorey², Baharia Mograbi³, Gérard Milano⁴

Affiliations

¹ Centre Antoine Lacassagne, Oncology Departement Unit, University Côte d'Azur, 06000 Nice, France.
² Centre Antoine Lacassagne, Epidemiology and Biostatistics Department, University Côte d'Azur, 06000 Nice, France.
³ IRCAN Group, University Côte d'Azur, 06000 Nice, France.
⁴ Centre Antoine Lacassagne, University Côte d'Azur, 33 Avenue de Valombrose, 06189 Nice, France.

PMID: 38399265
PMCID: PMC10893490
DOI: 10.3390/pharmaceutics16020211

Abstract

Artificial intelligence (AI) is progressively spreading through the world of health, particularly in the field of oncology. AI offers new, exciting perspectives in drug development as toxicity and efficacy can be predicted from computer-designed active molecular structures. AI-based in silico clinical trials are still at their inception in oncology but their wider use is eagerly awaited as they should markedly reduce durations and costs. Health authorities cannot neglect this new paradigm in drug development and should take the requisite measures to include AI as a new pillar in conducting clinical research in oncology.

Keywords: artificial intelligence; new drug discovery; oncology; serendipity.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

**Figure 1**
Different stages of AI-assisted in silico drug development.

See this image and copyright information in PMC

Cited by

Exploring the role of artificial intelligence in chemotherapy development, cancer diagnosis, and treatment: present achievements and future outlook.
Abdul Rasool Hassan B, Mohammed AH, Hallit S, Malaeb D, Hosseini H. Abdul Rasool Hassan B, et al. Front Oncol. 2025 Feb 4;15:1475893. doi: 10.3389/fonc.2025.1475893. eCollection 2025. Front Oncol. 2025. PMID: 39990683 Free PMC article.
The Imidazacridine Derivative LPSF/AC-05 Induces Apoptosis, Cell Cycle Arrest, and Topoisomerase II Inhibition in Breast Cancer, Leukemia, and Lymphoma.
de Oliveira Chagas MB, Mendonca da Costa VC, Montenegro C, de Lima MDCA, da Rosa MM, Pereira MC, de Melo Rego MJB, da Rocha Pitta MG. de Oliveira Chagas MB, et al. Curr Cancer Drug Targets. 2025;25(5):431-444. doi: 10.2174/0115680096290753240613114122. Curr Cancer Drug Targets. 2025. PMID: 38982694
Advances and critical aspects in cancer treatment development using digital twins.
Bouriga R, Bailleux C, Gal J, Chamorey E, Mograbi B, Hannoun-Levi JM, Milano G. Bouriga R, et al. Brief Bioinform. 2025 May 1;26(3):bbaf237. doi: 10.1093/bib/bbaf237. Brief Bioinform. 2025. PMID: 40458986 Free PMC article. Review.
Companion Tests and Personalized Cancer Therapy: Reaching a Glass Ceiling.
Ferrari V, Mograbi B, Gal J, Milano G. Ferrari V, et al. Int J Mol Sci. 2024 Sep 17;25(18):9991. doi: 10.3390/ijms25189991. Int J Mol Sci. 2024. PMID: 39337479 Free PMC article. Review.

References

1. Subbiah V. The next generation of evidence-based medicine. Nat. Med. 2023;29:49–58. doi: 10.1038/s41591-022-02160-z. - DOI - PubMed
1. Schilsky R.L., Longo D.L. Closing the Gap in Cancer Genomic Testing. N. Engl. J. Med. 2022;387:2107–2110. doi: 10.1056/NEJMp2210638. - DOI - PubMed
1. Elkhader J., Elemento O. Artificial intelligence in oncology: From bench to clinic. Semin. Cancer Biol. 2022;84:113–128. doi: 10.1016/j.semcancer.2021.04.013. - DOI - PubMed
1. Rani P., Dutta K., Kumar V. Artificial intelligence techniques for prediction of drug synergy in malignant diseases: Past, present, and future. Comput. Biol. Med. 2022;144:105334. doi: 10.1016/j.compbiomed.2022.105334. - DOI - PubMed
1. Passi I., Salwan S., Kumar B. US-FDA Approved Drugs in 2020 and 2021: A Review. Mini-Rev. Med. Chem. 2023;23:1273–1297. doi: 10.2174/1389557523666221208104530. - DOI - PubMed

LinkOut - more resources

Full Text Sources

[1] Subbiah V. The next generation of evidence-based medicine. Nat. Med. 2023;29:49–58. doi: 10.1038/s41591-022-02160-z. - DOI - PubMed

[2] Subbiah V. The next generation of evidence-based medicine. Nat. Med. 2023;29:49–58. doi: 10.1038/s41591-022-02160-z. - DOI - PubMed

[3] Schilsky R.L., Longo D.L. Closing the Gap in Cancer Genomic Testing. N. Engl. J. Med. 2022;387:2107–2110. doi: 10.1056/NEJMp2210638. - DOI - PubMed

[4] Schilsky R.L., Longo D.L. Closing the Gap in Cancer Genomic Testing. N. Engl. J. Med. 2022;387:2107–2110. doi: 10.1056/NEJMp2210638. - DOI - PubMed

[5] Elkhader J., Elemento O. Artificial intelligence in oncology: From bench to clinic. Semin. Cancer Biol. 2022;84:113–128. doi: 10.1016/j.semcancer.2021.04.013. - DOI - PubMed

[6] Elkhader J., Elemento O. Artificial intelligence in oncology: From bench to clinic. Semin. Cancer Biol. 2022;84:113–128. doi: 10.1016/j.semcancer.2021.04.013. - DOI - PubMed

[7] Rani P., Dutta K., Kumar V. Artificial intelligence techniques for prediction of drug synergy in malignant diseases: Past, present, and future. Comput. Biol. Med. 2022;144:105334. doi: 10.1016/j.compbiomed.2022.105334. - DOI - PubMed

[8] Rani P., Dutta K., Kumar V. Artificial intelligence techniques for prediction of drug synergy in malignant diseases: Past, present, and future. Comput. Biol. Med. 2022;144:105334. doi: 10.1016/j.compbiomed.2022.105334. - DOI - PubMed

[9] Passi I., Salwan S., Kumar B. US-FDA Approved Drugs in 2020 and 2021: A Review. Mini-Rev. Med. Chem. 2023;23:1273–1297. doi: 10.2174/1389557523666221208104530. - DOI - PubMed

[10] Passi I., Salwan S., Kumar B. US-FDA Approved Drugs in 2020 and 2021: A Review. Mini-Rev. Med. Chem. 2023;23:1273–1297. doi: 10.2174/1389557523666221208104530. - DOI - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Artificial Intelligence and Anticancer Drug Development-Keep a Cool Head

Affiliations

Artificial Intelligence and Anticancer Drug Development-Keep a Cool Head

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

Similar articles

Cited by

References

LinkOut - more resources

Full Text Sources